{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifpuuq5skzscrcc753o3peqjsvggll2kwonyz6m42jqmfx2vbrc6m",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mjmyd3dr6e22"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiakdsytshrhu3f3dzv46mheukblat2ily5srmgnk7tdhnzw5luttu"
    },
    "mimeType": "image/jpeg",
    "size": 324541
  },
  "path": "/news/2026-04-kind-drug-aims-heart-effectiveness.html",
  "publishedAt": "2026-04-16T13:00:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A team of University of Alberta researchers has developed a cardio-oncology drug that protects the heart from chemotherapy damage while enhancing the effectiveness of cancer treatments against tumor growth and spread. In a paper published as the cover story in Science Translational Medicine, the team identifies the target protein ZNF281 and a new drug they've developed called ZIM, or ZNF281 Interfering Molecule.",
  "title": "First-of-its-kind drug aims to protect the heart while increasing effectiveness of cancer treatments"
}